Generic placeholder image

Current Drug Targets


ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Acute Severe Colitis: Infliximab and/or Cyclosporine?

Author(s): Mauro Fabro, Hajnalka Szabo, Giovanni Terrosu, Claudio Avellini, Maria Tabuso, Gionata Fiorino and Dario Sorrentino

Volume 12, Issue 10, 2011

Page: [1448 - 1453] Pages: 6

DOI: 10.2174/138945011796818234

Price: $65


Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality rate of nearly 1%.

As of today, I.V. corticosteroids remain the 1st-line therapy for this complication. For non-responders (up to one-third of patients) possible options are surgery - whose timing is a critical point in the overall management of the disease - or rescue therapy with 2nd- line agents such as Cyclosporine and Infliximab. Here we will review the published studies dealing with the use of these medications in acute severe ulcerative colitis.

Keywords: Severe Colitis, Corticosteroids, Cyclosporine, Infliximab, Colectomy, Sigmoidoscopy

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy